Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Counihan, Donald
NCT04743141: Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine	Recruiting	3	200	Europe, US	Rimegepant / BHV3000	Pfizer	Acute Treatment of Migraine	12/24	05/27
REFOCUS-ALZ, NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease	Active, not recruiting	3	1083	Canada, US, RoW	Simufilam, PTI-125, Placebo	Cassava Sciences, Inc., Premier Research Group plc	Alzheimer Disease	05/25	05/25
NCT04649242 / 2020-003517-35: Randomized Study in Children and Adolescents With Migraine: Acute Treatment	Recruiting	3	2100	Europe, Canada, Japan, US, RoW	Rimegepant/BHV3000, Matching placebo	Pfizer	Pediatric Migraine	10/26	07/31
NCT04804033: A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention	Terminated	2/3	535	US	BHV-3500 (zavegepant), Placebo	Pfizer	Migraine	03/24	03/24